Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
62%51%40%Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 21 • YES 51.0%May 22 • YES 52.2%May 23 • YES 46.4%May 24 • YES 54.7%
Revolution Medicines, Inc. ($RVMD)
No stock closeNo stock close$142.9$115.8$88.81Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24Apr 6 • RVMD $95.36Apr 7 • RVMD $96.29Apr 8 • RVMD $96.75Apr 9 • RVMD $96.22Apr 10 • RVMD $96.43Apr 13 • RVMD $136.3
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
YESAccepted96% confidenceGPT-5.5 (OpenAI)
Question
Will this trial show a positive result on overall survival (OS) in the RAS G12-mutant population?
Found
Outcome Date
Reviewed
Summary

Sponsor topline readout for exact Phase 3 RASolute 302/NCT06625320 says the trial met all primary endpoints, including OS; the release defines primary OS in patients with RAS G12-mutant tumors and frames the OS benefit as statistically significant, clinically meaningful, and unprecedented.

Sources
Sponsorir.revmed.com
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Positive topline results: trial met all primary and key secondary endpoints, including OS; primary endpoints were PFS and OS in tumors harboring RAS G12 mutations.

Stats
Latest Run
Model
GPT-5.5 (OpenAI)
Runs
1 run